深圳商报·读创客户端记者李薇 阿斯利康在2026年上半年遭遇了一个颇具标志意义的转折:其中国区营收出现了近年来的首次半年度下滑。根据7月27日发布的财报,虽然公司全球总营收达到306.72亿美元,同比增长6%,肿瘤板块更是凭借Enhertu(德曲妥珠单抗)等产品表现强劲,上涨15%至141.23亿美元,但在中国市场上,35.1亿美元的营收较去年同期缩水了5%。 这一变化并非偶然的短期震荡,而是...
Source Link深圳商报·读创客户端记者李薇 阿斯利康在2026年上半年遭遇了一个颇具标志意义的转折:其中国区营收出现了近年来的首次半年度下滑。根据7月27日发布的财报,虽然公司全球总营收达到306.72亿美元,同比增长6%,肿瘤板块更是凭借Enhertu(德曲妥珠单抗)等产品表现强劲,上涨15%至141.23亿美元,但在中国市场上,35.1亿美元的营收较去年同期缩水了5%。 这一变化并非偶然的短期震荡,而是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.